Comparative Pharmacology
Head-to-head clinical analysis: FERRISELTZ versus NEXESTA FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERRISELTZ versus NEXESTA FE.
FERRISELTZ vs NEXESTA FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ferric iron (Fe3+) from ferric citrate reduces phosphate absorption by forming insoluble ferric phosphate complexes in the gastrointestinal tract, reducing serum phosphate levels. Iron is absorbed and incorporated into hemoglobin.
Norepinephrine-dopamine reuptake inhibitor (NDRI); weakly inhibits serotonin reuptake. Also releases norepinephrine from presynaptic neurons.
325-650 mg orally once daily; ferrous sulfate 325 mg (equivalent to 65 mg elemental iron).
One tablet (containing 1 mg norethindrone acetate and 1.5 mg ethinyl estradiol) orally once daily for 28-day cycle.
None Documented
None Documented
Not applicable for iron absorption; serum iron levels peak at 1-2 hours post-dose and decline with a half-life of approximately 6 hours, reflecting gastrointestinal absorption and distribution.
Terminal half-life: 4-6 hours; clinical context: dosing every 4-6 hours for pain.
Ferric citrate is primarily eliminated via feces as unabsorbed drug (approximately 70-80%). A small fraction is absorbed and excreted renally (less than 1% of ingested dose).
Renal: 20-30% unchanged; fecal/biliary: 70-80% as metabolites.
Category C
Category C
Iron Supplement
Iron Supplement